Show simple item record

dc.contributor.authorOusley, J
dc.contributor.authorSoe, KP
dc.contributor.authorKyaw, NTT
dc.contributor.authorAnicete, R
dc.contributor.authorMon, PE
dc.contributor.authorLwin, H
dc.contributor.authorWin, T
dc.contributor.authorCristofani, S
dc.contributor.authorTelnov, A
dc.contributor.authorFernandez, M
dc.contributor.authorCiglenecki, I
dc.date.accessioned2018-04-06T21:05:00Z
dc.date.available2018-04-06T21:05:00Z
dc.date.issued2018-03-21
dc.date.submitted2018-04-06
dc.identifier.citationIPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence. 2018, 8 (1):20-24 Public Health Actionen
dc.identifier.issn2220-8372
dc.identifier.pmid29581939
dc.identifier.doi10.5588/pha.17.0087
dc.identifier.urihttp://hdl.handle.net/10144/619087
dc.description.abstractSetting: A southern Myanmar district providing isoniazid preventive therapy (IPT) in one of the last countries to formally recommend it as part of human immunodeficiency virus (HIV) care.Objective:To assess coverage and adherence and the feasibility of IPT scale-up in a routine care setting in Myanmar.Design:A retrospective analysis of people living with HIV (PLHIV) screened for tuberculosis (TB) and enrolled in IPT over a 3-year period (July 2011-June 2014) using clinical databases.Results:Among 3377 patients under HIV care and screened for TB, 2740 (81.1%) initiated IPT, with 2651 (96.8%) completing a 6- or 9-month course of IPT; 83 (3.1%) interrupted treatment for different reasons, including loss to follow-up (n= 41), side effects (n= 15) or drug adherence issues (n= 9); 6 (0.2%) died. Among the IPT patients, 33 (1.2%) were diagnosed with TB, including 9 (0.3%) while on IPT and 24 (0.9%) within 1 year of completion of therapy. Among the PLHIV who completed IPT, one case of isoniazid resistance was detected.Conclusion:Scaling up IPT in Myanmar HIV settings is feasible with high rates of drug adherence and completion, and a low rate of discontinuation due to side effects. IPT scale-up should be prioritised in HIV clinical settings in Myanmar.
dc.language.isoenen
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen
dc.rightsArchived with thanks to Public Health Actionen
dc.titleIPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherenceen
dc.identifier.journalPublic Health Actionen
refterms.dateFOA2019-03-04T13:46:43Z
html.description.abstractSetting: A southern Myanmar district providing isoniazid preventive therapy (IPT) in one of the last countries to formally recommend it as part of human immunodeficiency virus (HIV) care.Objective:To assess coverage and adherence and the feasibility of IPT scale-up in a routine care setting in Myanmar.Design:A retrospective analysis of people living with HIV (PLHIV) screened for tuberculosis (TB) and enrolled in IPT over a 3-year period (July 2011-June 2014) using clinical databases.Results:Among 3377 patients under HIV care and screened for TB, 2740 (81.1%) initiated IPT, with 2651 (96.8%) completing a 6- or 9-month course of IPT; 83 (3.1%) interrupted treatment for different reasons, including loss to follow-up (n= 41), side effects (n= 15) or drug adherence issues (n= 9); 6 (0.2%) died. Among the IPT patients, 33 (1.2%) were diagnosed with TB, including 9 (0.3%) while on IPT and 24 (0.9%) within 1 year of completion of therapy. Among the PLHIV who completed IPT, one case of isoniazid resistance was detected.Conclusion:Scaling up IPT in Myanmar HIV settings is feasible with high rates of drug adherence and completion, and a low rate of discontinuation due to side effects. IPT scale-up should be prioritised in HIV clinical settings in Myanmar.


Files in this item

Thumbnail
Name:
Ousley et al - 2018 - IPT during ...
Size:
281.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record